Exhibit 10.4
HOMOLOGY MEDICINES, INC.
AMENDMENT TO EMPLOYMENT AGREEMENT
This AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is entered into effective as of September 6, 2022, by and between Homology Medicines, Inc. (the “Company”) and Paul Alloway (“Executive,” and, together with the Company, the “Parties”).
WHEREAS, the Parties entered into the Employment Agreement, dated as of March 18, 2020 (the “Agreement”); and
NOW, THEREFORE, in consideration of the promises, mutual covenants, and the agreements herein set forth, and for other good and valuable consideration, the sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:
“(i) an amount in cash equal to 1.0 times the Annual Base Salary, payable in the form of salary continuation in regular installments over the 12-month period following the date of Executive’s Separation from Service (the “Severance Period”) in accordance with the Company’s normal payroll practices.”
(Signature page follows)
IN WITNESS WHEREOF, the Parties have each duly executed this AMENDMENT TO EMPLOYMENT AGREEMENT effective as of the date and year first written above.
HOMOLOGY MEDICINES, INC. |
By: /s/ W. Bradford Smith |
Name: W. Bradford Smith |
Title: Chief Financial and Business Officer |
EMPLOYEE: |
/s/ Paul Alloway |
Name: Paul Alloway |